An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status

Sheila Lumley, Gillian Rodger, Bede Constantinides, Nicholas Sanderson, Kevin Chau, Teresa Street, Denise O’Donnell, Alison Howarth, Stephanie B. Hatch, Brian D. Marsden, Stuart Cox, Tim James, Fiona C Warren, Liam J Peck, Thomas Ritter, Zoe de Toledo, Laura Warren, David Axten, Richard J. Cornall, E. Yvonne Jones, David I. Stuart, Gavin Screaton, Daniel Ebner, Sarah Hoosdally, Meera Chand, Derrick W. Crook, Colm P. O’Donnell, Christopher P. Conlon, Koen B. Pouwels, A. Sarah Walker, Tim Peto, Susan Hopkins, Nicole Stoesser, Philippa C Matthews, Katie Jeffery, David W. EyremedRxiv 2021 · DOI

Abstract

Natural and vaccine-induced immunity are critical for controlling the SARS-CoV-2 pandemic. However, the emergence of variants like B.1.1.7 (Alpha) raised concerns regarding potential immune evasion. In this longitudinal cohort study of 13,109 healthcare workers (HCWs) in Oxfordshire, UK, we investigated the protection against symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infection conferred by vaccination (Pfizer-BioNTech BNT162b2 or Oxford-AstraZeneca ChAdOx1 nCOV-19) and prior infection. Our results demonstrate that both natural infection (detectable anti-spike antibodies) and two-dose vaccination provide robust protection (≥85%) against infection, including the B.1.1.7 variant.

Introduction

In early 2021, the global pandemic response faced two significant challenges: the real-world validation of vaccine efficacy outside of clinical trials and the emergence of the B.1.1.7 (Alpha) variant. While initial trials for the Pfizer-BioNTech and Oxford-AstraZeneca vaccines showed high efficacy, their performance in high-exposure environments—such as hospital settings—and against emerging lineages remained to be fully characterized. This study sought to quantify the protection offered by vaccination (comparing one versus two doses) and natural immunity, specifically assessing resilience against the B.1.1.7 variant.

Methods

The researchers conducted a longitudinal cohort study of 13,109 healthcare workers at Oxford University Hospitals (OUH) between September 2020 and February 2021.

Participant Classification

HCWs were categorized into three primary groups based on their status at the start of the study:

  1. Unvaccinated/Seronegative: No prior infection and no vaccine doses.
  2. Unvaccinated/Seropositive: Evidence of natural immunity via detectable anti-spike antibodies.
  3. Vaccinated: Received either one or two doses of BNT162b2 or ChAdOx1 nCOV-19.

Testing and Surveillance

The study utilized a comprehensive testing regimen including voluntary asymptomatic screening (PCR every two weeks), symptomatic testing, and regular serological (antibody) testing. To identify the B.1.1.7 variant, the team monitored S-gene target failure (SGTF) in PCR assays as a proxy and confirmed lineages using Oxford Nanopore whole-genome sequencing (WGS).

Statistical Analysis

Poisson regression was used to calculate adjusted incidence rate ratios (aIRRs), accounting for variables such as age, sex, ethnicity, and occupational risk (e.g., working on a COVID-19 ward). The primary dataset was generated by the OUH staff testing program, with genomic data archived in the European Nucleotide Archive (accession PRJEB43319).

Results

The study population included 8,285 HCWs who received the Pfizer-BioNTech vaccine and 2,738 who received the Oxford-AstraZeneca vaccine.

Protection Against Symptomatic Infection

Compared to the unvaccinated seronegative group, both natural immunity and a two-dose vaccine regimen provided near-total protection. No HCW who received two vaccine doses experienced a symptomatic infection during the study period. Natural immunity (seropositivity) was associated with a 98% reduction in symptomatic infection (aIRR 0.02 [95%CI <0.01-0.18]). A single vaccine dose offered a 67% reduction (aIRR 0.33 [0.21-0.52]).

Protection Against Any PCR-Positive Result

When considering all PCR-positive results (including asymptomatic cases), two vaccine doses provided 90% protection (0.10 [0.02-0.38]), while natural immunity provided 85% protection (0.15 [0.08-0.26]). A single dose reduced the incidence of any PCR-positive result by 64% (0.36 [0.26-0.50]).

B.1.1.7 Variant and Viral Load

There was no evidence of reduced protection against the B.1.1.7 variant compared to other lineages. Furthermore, breakthrough infections in vaccinated or previously infected individuals were characterized by significantly lower viral loads (indicated by higher Ct values), suggesting a potential reduction in transmissibility even when infection occurred.

Discussion

The findings highlight a "parity of protection" between natural immunity and full vaccination. The observation that natural infection resulting in detectable antibodies provides protection comparable to two vaccine doses was a critical insight for understanding population-level immunity during the early stages of the vaccine rollout.

The data also underscored the importance of the second vaccine dose. While a single dose provided substantial protection against symptomatic disease, the significant increase in protection against any infection (including asymptomatic carriage) after the second dose suggests that the full schedule is vital for breaking chains of transmission.

Limitations

The study's cohort primarily consisted of healthy, working-age adults, which may limit the generalizability of the findings to elderly or pediatric populations. Additionally, because testing was voluntary, there is a possibility of testing bias; individuals who felt protected by vaccination or prior infection might have been less likely to seek testing. Finally, while the study confirmed protection against B.1.1.7, the emergence of subsequent variants requires ongoing surveillance to determine the long-term durability of this immunity.

Conclusion

Both natural infection and two-dose vaccination provide robust, high-level protection against SARS-CoV-2 infection. Crucially, this immunity remains effective against the B.1.1.7 variant. These findings support the continued prioritization of full vaccination schedules to control the spread of the virus and protect high-risk populations like healthcare workers.

Summary updated

Abstract

Abstract Background Natural and vaccine-induced immunity will play a key role in controlling the SARS-CoV-2 pandemic. SARS-CoV-2 variants have the potential to evade natural and vaccine-induced immunity. Methods In a longitudinal cohort study of healthcare workers (HCWs) in Oxfordshire, UK, we investigated the protection from symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infection conferred by vaccination (Pfizer-BioNTech BNT162b2, Oxford-AstraZeneca ChAdOx1 nCOV-19) and prior infection (determined using anti-spike antibody status), using Poisson regression adjusted for age, sex, temporal changes in incidence and role. We estimated protection conferred after one versus two vaccinations and from infections with the B.1.1.7 variant identified using whole genome sequencing. Results 13,109 HCWs participated; 8285 received the Pfizer-BioNTech vaccine (1407 two doses) and 2738 the Oxford-AstraZeneca vaccine (49 two doses). Compared to unvaccinated seronegative HCWs, natural immunity and two vaccination doses provided similar protection against symptomatic infection: no HCW vaccinated twice had symptomatic infection, and incidence was 98% lower in seropositive HCWs (adjusted incidence rate ratio 0.02 [95%CI &lt;0.01-0.18]). Two vaccine doses or seropositivity reduced the incidence of any PCR-positive result with or without symptoms by 90% (0.10 [0.02-0.38]) and 85% (0.15 [0.08-0.26]) respectively. Single-dose vaccination reduced the incidence of symptomatic infection by 67% (0.33 [0.21-0.52]) and any PCR-positive result by 64% (0.36 [0.26-0.50]). There was no evidence of differences in immunity induced by natural infection and vaccination for infections with S-gene target failure and B.1.1.7. Conclusion Natural infection resulting in detectable anti-spike antibodies and two vaccine doses both provide robust protection against SARS-CoV-2 infection, including against the B.1.1.7 variant. Summary Natural infection resulting in detectable anti-spike antibodies and two vaccine doses both provided ≥ 85% protection against symptomatic and asymptomatic SARS-CoV-2 infection in healthcare workers, including against the B.1.1.7 variant. Single dose vaccination reduced symptomatic infection by 67%.
BibTeX
@misc{lumley2021observational,
  author = {Sheila Lumley and Gillian Rodger and Bede Constantinides and Nicholas Sanderson and Kevin Chau and Teresa Street and Denise O’Donnell and Alison Howarth and Stephanie B. Hatch and Brian D. Marsden and Stuart Cox and Tim James and Fiona C Warren and Liam J Peck and Thomas Ritter and Zoe de Toledo and Laura Warren and David Axten and Richard J. Cornall and E. Yvonne Jones and David I. Stuart and Gavin Screaton and Daniel Ebner and Sarah Hoosdally and Meera Chand and Derrick W. Crook and Colm P. O’Donnell and Christopher P. Conlon and Koen B. Pouwels and A. Sarah Walker and Tim Peto and Susan Hopkins and A Sarah Walker and Nicole Stoesser and Philippa C Matthews and Katie Jeffery and David W. Eyre},
  title = {{An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status}},
  year = {2021},
  doi = {10.1101/2021.03.09.21253218},
  howpublished = {medRxiv},
}
Figure